JACKIE DUNCAN: Open Payments
NPI 1740431998 · FLINT, MI. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,356 in 105 payments from 12 companies in 2025. Trend: 2023 $1,443 · 2024 $2,401 · 2025 $2,356
Food & beverage: $2,356
| Company | Payments | Amount |
|---|---|---|
| Neurocrine BioSciences, Inc. | 24 | $395 |
| Otsuka America Pharmaceutical, Inc. | 17 | $379 |
| Alkermes, Inc. | 14 | $255 |
| Vanda Pharmaceuticals Inc. | 5 | $243 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 7 | $240 |
| ABBVIE INC. | 12 | $188 |
| Teva Pharmaceuticals USA, Inc. | 6 | $182 |
| E.R. Squibb & Sons, L.L.C. | 8 | $180 |
| Lundbeck LLC | 7 | $179 |
| Janssen Pharmaceuticals, Inc | 3 | $73 |
Products named: REXULTI, INGREZZA, FANAPT, CAPLYTA, ARISTADA, VRAYLAR, COBENFY, UZEDY.
Industry payments across MI — which companies pay providers there.
